Acquisition of therapy resistance is frequently driven by altered AR functions, including enhancer switching to novel gene regulatory regions(2) that favor growth promotion instead of differentiation(3–7) and the acquisition of alternative lineages, such as neuroendocrine (NE) PCa. Here, AR is linked to posterior cortical atrophy.